3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
No longer available
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Ipilimumab
114
pembrolizumab
95
Nivolumab
91
aldesleukin
86
Interleukin-2
57
Cyclophosphamide
54
Dacarbazine
52
Vemurafenib
39
trametinib
37
Temozolomide
37
incomplete Freund's adjuvant
35
fludarabine phosphate
35
sargramostim
32
dabrafenib
32
fludarabine
26
Bevacizumab
26
Paclitaxel
22
MART-1 Antigen
21
Granulocyte-Macrophage Colony-Stimulating Factor
21
montanide ISA 51
20
Interferon-alpha
20
Cisplatin
20
Carboplatin
19
Sorafenib
18
Introns
17
Biopsy
17
cobimetinib
16
Radiosurgery
16
atezolizumab
15
Radiotherapy
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Melanoma
×
AM0010
×
Clear all
NCT02009449
2024-11-15
IVY
Eli Lilly and Company
Phase 1
Completed
353 enrolled